Back to Agenda
PMDA Town Hall
Session Chair(s)
Nobumasa Nakashima
Professor, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Japan
PMDA’s activity is based on "4Fs" (Patient First, Access First, Safety First, Asia First) as priority policy, which Dr. Fujiwara, chief executive, has set up. In this session, PMDA will introduce its efforts around "4Fs" including those for COVID19.
Learning Objective : Describe the latest information regarding PMDA and Japanese regulations; Discuss how to foster dialogue between participants and senior PMDA officials concerning drug/device regulatory challenges.
Speaker(s)
Fumi Yamamoto
Councilor for Pharmaceutical Affairs, Minister’s Secretariat, Ministry of Health, Labour and Welfare (MHLW), Japan
Panelist
Yasuhiro Fujiwara, MD, PHD
Chief Executive, Pharmaceuticals and Medical Devices Agency (PMDA), Japan
Panelist
Kenichi Tamiya, MSC, RPH
Associate Executive Director, Office of New Drug, Pharmaceuticals and Medical Devices Agency (PMDA), Japan
Panelist
Have an account?
